Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated). Therapeutic indications:
Sofosvel is indicated for the treatment of adult patients
Product Name | Sofosvel |
Generic Name | Sofosbuvir+Velpatasvir |
Formulation | Tablet |
Available Pack Size | 1x28's |
Available Strength | 400 mg |